180 related articles for article (PubMed ID: 20371030)
1. The efficacy, tolerability, and safety of contemporary antidepressants.
Papakostas GI
J Clin Psychiatry; 2010; 71 Suppl E1():e03. PubMed ID: 20371030
[TBL] [Abstract][Full Text] [Related]
2. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials.
Haberfellner EM
Pharmacopsychiatry; 2007 Sep; 40(5):173-82. PubMed ID: 17874347
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
McIntyre RS; Muzina DJ; Adams A; Lourenco MT; Law CW; Soczynska JK; Woldeyohannes HO; Nathanson J; Kennedy SH
Expert Opin Pharmacother; 2009 Dec; 10(18):3061-75. PubMed ID: 19954275
[TBL] [Abstract][Full Text] [Related]
5. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression.
Ghaemi SN
Bipolar Disord; 2008 Dec; 10(8):957-68. PubMed ID: 19594510
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of antidepressants: weighing the impact on treatment decisions.
Schatzberg AF
J Clin Psychiatry; 2007; 68 Suppl 8():26-34. PubMed ID: 17640155
[TBL] [Abstract][Full Text] [Related]
12. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
Perry R; Cassagnol M
Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
[TBL] [Abstract][Full Text] [Related]
14. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Munizza C; Olivieri L; Di Loreto G; Dionisio P
Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
[TBL] [Abstract][Full Text] [Related]
15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders.
Gupta S; Nihalani N; Masand P
Ann Clin Psychiatry; 2007; 19(2):125-32. PubMed ID: 17612852
[TBL] [Abstract][Full Text] [Related]
17. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]